<\/p>\n\n\n
Manufacturers & Distributors<\/p>\n\n\n
Vision 2030 mandates local production. Manufacturers have factories and licenses \u2014 but lack the products, dossiers, and technical know-how to scale. Distributors need differentiated, compliant portfolios. That’s how we build \u2014 the missing pieces integrated into the value chain you already have.<\/p>\n\n\n\n
<\/p>\n\n\n
MEA Pharma Market by 2034<\/p>\n<\/div>\n\n\n\n
Currently Imported<\/p>\n<\/div>\n\n\n\n
Local Production Target<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n
<\/p>\n\n\n
Four Capabilities<\/p>\n\n\n
Local production only scales when portfolio, dossiers, studies, and manufacturing partners are integrated into one growth path. That’s Takamul<\/strong> applied to manufacturers and distributors.<\/p>\n\n\n\n \ud83d\udcca<\/p>\n\n\n\n Portfolio Strategy<\/p>\n\n\n Integrated with your existing licenses and territory to identify the products worth making.<\/p>\n\n\n\n Data + territory + white space = the right products to make<\/p>\n<\/div>\n<\/div>\n\n\n\n \ud83d\udcc4<\/p>\n\n\n\n Dossiers & Tech Packs<\/p>\n\n\n Integrated with local regulatory submissions to shorten time to launch.<\/p>\n\n\n\n Ready dossiers + tech transfer = launch in under 3 years<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n \ud83e\uddea<\/p>\n\n\n\n BE Studies Managed<\/p>\n\n\n Integrated end-to-end to cut failure risk and keep studies on timeline.<\/p>\n\n\n\n Experienced CROs + oversight = studies that pass<\/p>\n<\/div>\n<\/div>\n\n\n\n \ud83c\udfed<\/p>\n\n\n\n CDMO Identification<\/p>\n\n\n Integrated with your manufacturing footprint for competitive, compliant supply.<\/p>\n\n\n\n Audited partners + fit = compliant, competitive supply<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n <\/p>\n\n\n Why It Works<\/p>\n\n\n In-licensed dossiers, ready tech packs, and molecule-experienced CRO access cut the timeline in half \u2014 without internal R&D investment.<\/p>\n\n\n\n Going Alone<\/p>\n\n\n With AMRA<\/p>\n\n\n <\/p>\n\n\n Integrated Impact<\/p>\n\n\n Manufacturers and distributors each get the missing pieces integrated into the business they already run \u2014 not a generic consulting retainer.<\/p>\n\n\n\n \ud83c\udfed<\/p>\n<\/div>\n\n\n\n Local Manufacturers<\/p>\n\n\n Portfolio strategy, pre-validated dossiers, managed BE studies, and CDMO matching \u2014 integrated with your existing factory and licenses to compress time-to-market and expand the products you can profitably make.<\/p>\n<\/div>\n<\/div>\n\n\n\n \ud83d\ude9a<\/p>\n<\/div>\n\n\n\n Distributors<\/p>\n\n\n Portfolio access via in-licensed products and exclusive molecules, compliant sourcing through pre-vetted CMOs, and faster registration through pre-validated dossiers \u2014 integrated to open new channels across the Meridian.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n <\/p>\n\n\n Ready to Scale Local Production<\/p>\n\n\n Partner with AMRA to integrate portfolio, dossiers, studies, and manufacturing into one growth path \u2014 from license to launch.<\/p>\n\n\n\nIn-licensing roadmap, white-space analysis, and therapeutic prioritisation<\/h3>\n\n\n\n
Pre-validated dossiers and ready tech-transfer packages<\/h3>\n\n\n\n
Molecule-experienced CRO matching, study oversight, and compliance<\/h3>\n\n\n\n
A curated, audited partner network selected for cost and quality fit<\/h3>\n\n\n\n
From 6 Years to Under 3<\/h2>\n\n\n\n
6 Years<\/h3>\n\n\n
\n
Under 3 Years<\/h3>\n\n\n
\n
Built for Both Sides of the Value Chain<\/h2>\n\n\n\n
From commodity competition to branded-generic margins<\/h3>\n\n\n\n
Differentiated, compliant portfolios that win tenders<\/h3>\n\n\n\n
Ready to Turn Your Factory Into a Portfolio?<\/h2>\n\n\n\n